|
|
|
|
|
Click Here to return To Results
|
|
|
|
The SBB was diagnostic in 25 patients (96%). Potentially treatable disease was diagnosed in 21 patients (81%), and specific therapy was initiated in 17 patients (65%); 10 patients (39%) were able to complete therapy. The SBB corroborated the clinical diagnosis in 13 (52%) of 25 patients. The group with identical clinical and biopsy-proved diagnoses showed significantly better response to therapy (P = .02), clinical performance (P = .04, and survival after biopsy (P = .01), as compared w ith the group with different clinical and biopsy-proved diagnosis, although no significant difference was found for the degree of immunosuppression. Only completion of the treatment plan increased life expectancy significantly (P = .008). These data sho w that in human immunodeficiency virus-positive patients with brain mass lesions, SBB has a high diagnostic yield. A subgroup of patients will benefit from specific therapy guided by the SBB result. The procedure should, however, be strictly limited to patients able to tolerate specific therapy. |
|
(click to filter results - removes previous filter)
acquired immunodeficiency syndrome
algorithm
brain biopsy
brain biopsy,stereotaxic
human immunodeficiency virus type 1
life expectancy
lymphoma
lymphoma involving CNS
MRI,abnormal
MRI,mass effect on
neurologic disease,diagnoses of
practice guidelines
review article
toxoplasmosis,CNS
treatment of neurologic disorder
|
Click Here to return To Results
|
|